Pemetrexed + Erlotinib
ApprovedTerminated 1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Carcinoma, Non-Small-Cell Lung
Conditions
Carcinoma, Non-Small-Cell Lung
Trial Timeline
Feb 28, 2018 → Nov 14, 2018
NCT ID
NCT03460678About Pemetrexed + Erlotinib
Pemetrexed + Erlotinib is a approved stage product being developed by Hikma Pharmaceuticals for Carcinoma, Non-Small-Cell Lung. The current trial status is terminated. This product is registered under clinical trial identifier NCT03460678. Target conditions include Carcinoma, Non-Small-Cell Lung.
What happened to similar drugs?
20 of 20 similar drugs in Carcinoma, Non-Small-Cell Lung were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
20
Activity
0
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03460678 | Approved | Terminated |
Competing Products
20 competing products in Carcinoma, Non-Small-Cell Lung